J & J Spends $30B on Actelion Rare Disease Portfolio

As part of the transaction, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company

Source: PharmaManufacturing.com - January 27, 2017 Category: Pharmaceuticals Source Type: news